First Trust Advisors
CPRX

First Trust Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

First Trust Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.89M Sell
282,887
-63,357
-18% -$1.87M 0.01% 1262
2026
Q1 		$8.57M Buy
346,244
+254,902
+279% +$6.07M 0.01% 1166
2025
Q4 		$2.13M Sell
91,342
-93,798
-51% -$2.09M ﹤0.01% 1856
2025
Q3 		$3.65M Sell
185,140
-117,140
-39% -$2.41M ﹤0.01% 1538
2025
Q2 		$6.56M Buy
302,280
+60,114
+25% +$1.42M 0.01% 1235
2025
Q1 		$5.87M Sell
242,166
-1,991,668
-89% -$44.9M 0.01% 1237
2024
Q4 		$46.6M Sell
2,233,834
-195,139
-8% -$4.19M 0.04% 545
2024
Q3 		$48.3M Sell
2,428,973
-43,960
-2% -$815K 0.05% 515
2024
Q2 		$38.3M Buy
2,472,933
+2,248,850
+1,004% +$35M 0.04% 570
2024
Q1 		$3.57M Buy
224,083
+124,238
+124% +$1.87M ﹤0.01% 1463
2023
Q4 		$1.68M Buy
99,845
+5,476
+6% +$74.9K ﹤0.01% 1791
2023
Q3 		$1.1M Sell
94,369
-69,974
-43% -$936K ﹤0.01% 1931
2023
Q2 		$2.21M Buy
+164,343
New +$2.36M ﹤0.01% 1653
2023
Q1 		– Sell
-167,435
Closed -$3.11M – 2377
2022
Q4 		$3.11M Buy
+167,435
New +$2.58M ﹤0.01% 1487
2022
Q3 		– Sell
-142,629
Closed -$1M – 2494
2022
Q2 		$1M Sell
142,629
-4,402
-3% -$32.3K ﹤0.01% 1986
2022
Q1 		$1.22M Sell
147,031
-8,535
-5% -$60.3K ﹤0.01% 1977
2021
Q4 		$1.05M Buy
155,566
+19,408
+14% +$128K ﹤0.01% 2032
2021
Q3 		$722K Sell
136,158
-107,904
-44% -$590K ﹤0.01% 2154
2021
Q2 		$1.4M Sell
244,062
-9,501
-4% -$49K ﹤0.01% 1948
2021
Q1 		$1.17M Buy
253,563
+20,353
+9% +$80.9K ﹤0.01% 1937
2020
Q4 		$779K Sell
233,210
-10,106
-4% -$34K ﹤0.01% 1992
2020
Q3 		$723K Buy
+243,316
New +$951K ﹤0.01% 1900

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors's CPRX Position: Q2 2026 in Review

First Trust Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 18% in Q2 2026, selling an estimated $1.87M and leaving 282,887 shares worth $8.89M. The position accounts for 0.01% of the portfolio, ranked #1262.

First Trust Advisors first reported a position in CPRX in Q3 2020 and has held it in 22 quarters since. The position peaked at $48.3M in Q3 2024. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • First Trust Advisors held 282,887 shares of Catalyst Pharmaceutical worth $8.89M as of Q2 2026.
  • First Trust Advisors sold 63,357 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.87M.
  • Catalyst Pharmaceutical made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #1262 holding.
  • First Trust Advisors first reported a position in Catalyst Pharmaceutical in Q3 2020 and has held it in 22 quarters since.
  • First Trust Advisors's Catalyst Pharmaceutical position peaked at $48.3M in Q3 2024.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.